No retraction, correction or concern found when last checked on Oct 26, 2026.

Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity?

Rosa Vona, Elisabetta Iessi, Paola Matarrese

Frontiers in Cell and Developmental Biology · 2021 · Review · CC BY

doi:10.3389/fcell.2021.622908

Abstract

Cholesterol is a lipid molecule that plays an essential role in a number of biological processes, both physiological and pathological. It is an essential structural constituent of cell membranes, and it is fundamental for biosynthesis, integrity, and functions of biological membranes, including membrane trafficking and signaling. Moreover, cholesterol is the major lipid component of lipid rafts, a sort of lipid-based structures that regulate the assembly and functioning of numerous cell signaling pathways, including those related to cancer, such as tumor cell growth, adhesion, migration, invasion, and apoptosis. Considering the importance of cholesterol metabolism, its homeostasis is strictly regulated at every stage: import, synthesis, export, metabolism, and storage. The alterations of this homeostatic balance are known to be associated with cardiovascular diseases and atherosclerosis, but mounting evidence also connects these behaviors to increased cancer risks. Although there is conflicting evidence on the role of cholesterol in cancer development, most of the studies consistently suggest that a dysregulation of cholesterol homeostasis could lead to cancer development. This review aims to discuss the current understanding of cholesterol homeostasis in normal and cancerous cells, summarizing key findings from recent preclinical and clinical studies that have investigated the role of major players in cholesterol regulation and the organization of lipid rafts, which could represent promising therapeutic targets.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Cholesterol is a primary lipid molecule that plays an essential role in a number of biological processes, both at physiological and pathological level.

2Cholesterol, in addition to being an important constituent of cell membranes, is fundamental for their biogenesis, and is indispensable for maintaining integrity and functions of biological membranes, including endocytosis, membrane trafficking, and signaling. Inside the cell, cholesterol, heterogeneously distributed among the organelles, modulates the immune system, and represents a precursor of hormones such as sexual hormones and vitamin D (; Figure 1).

3Recently, cholesterol has played a key role in cancer research because of its potential therapeutic implications both in prevention and in treatment. However, the role of cholesterol in oncogenesis is still debated. Literature data reported a contradictory role of cholesterol depending on the type of tumor. Excess of cholesterol is related to breast, colon, rectal, prostatic, and testicular cancers, while some prospective cohort studies showed an inverse association in gastric and prostate cancers. This review aims to discuss the current knowledge of cholesterol homeostasis, critically analyzing the most recent preclinical and clinical studies investigating the role of the principal players of the cholesterol biosynthetic pathway, and of the cholesterol-based membrane structure’s lipid rafts in the field of cancer.

Cholesterol Metabolism

4Cholesterol is produced through a cascade of enzymatic reactions, namely, mevalonate pathway, which requires the participation of different enzymes localized on the membranes of the endoplasmic reticulum (ER). Briefly, the combination of three acetyl-CoA molecules leads to the formation of one 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) molecule. The latter, by the action of HMG-CoA reductase (HMGCR), is converted into mevalonate, in turn transformed into squalene (SQL), and ultimately into cholesterol by means of a number of reactions (Figure 2). Food can be a source of cholesterol too. In fact, the Niemann–Pick type C1-like 1 (NPC1L1) protein, present on the membrane of the intestinal enterocytes, is responsible for the absorption of cholesterol, which is released as chylomicrons, triglyceride-rich lipid particles, and is taken up by the liver.

5Cholesterol is mainly synthesized in the liver and free into the bloodstream as very-low-density lipoproteins (VLDLs). In the bloodstream, the VLDLs are transformed to produce low-density lipoproteins (LDLs), transported to peripheral cells by the bloodstream. LDLs enter cells via receptor (LDLR)-mediated endocytosis and are transported to lysosomes where they are hydrolyzed into free cholesterol molecules, which are transported to cellular membranes to carry out its multiple functions.

6Mevalonate pathway is tightly regulated by transcriptional and translational mechanisms capable of responding to physiological signals. Cholesterol biosynthesis is regulated by four principal players: (1) sterol regulatory element-binding protein 2 (SREBP2), which acts through a negative feedback mechanism, (2) liver X Receptors (LXRs), (3) HMGCR, and (4) squalene epoxidase (SQLE). HMGCR and SQLE are rate-limiting enzymes, which can regulate cholesterol biosynthesis, the reactions they catalyze being energetically expensive. When intracellular ATP levels are low, 5′adenosine monophosphate-activated protein kinase (AMPK) phosphorylates HMGCR inhibiting its function. Moreover, HMGCR is influenced by the presence of LDL in the medium; in fact, upon LDL starvation, HMGCR activity enhances, while it highly decreases when LDL is added back. On the other hand, once cholesterol has exhausted its function, its surplus is exported via ATP-binding cassette (ABC) subfamily A member 1 (ABCA1) or ABC subfamily G member 1 (ABCG1) to lipid-poor apolipoprotein A-I (ApoA-I), thus generating high-density lipoproteins (HDLs). The transcription of ABCA1 is upregulated by nuclear LXRs when the intracellular cholesterol level is high. The CoA:cholesteryl acyltransferase 1 (ACAT1) transforms excess cholesterol into less toxic compounds, such as cholesteryl esters (CEs), which are stored as lipid droplets and used for the production of the main plasma lipoproteins (chylomicrons, VLDLs, LDLs, and HDLs). HDLs are then transported from peripheral tissues back to the liver and intestine, to recycle or eliminate cholesterol, and to steroidogenic organs, where cholesterol is used to generate steroid hormone.

7Recent studies on microRNAs (miRNAs), a class of non-coding RNAs, highlighted their role in the cholesterol homeostasis by adjusting some important components of the system. For instance, under low sterol concentration conditions, higher transcription of miR-33a is required to control cholesterol export and HDL metabolism through ABCA1 inhibition. Conversely, miR-223 regulates cholesterol amount by inhibiting its production and ameliorating cholesterol efflux by enhancing ABCA1 levels. miRNA-122, present mainly in hepatocytes, when inhibited significantly suppresses blood cholesterol level. miR-27a has been shown to control HMGCR level either by a posttranslational block or by mRNA degradation. Strikingly, other miRNAs have been discovered by meta-analyses to be associated with cholesterol–lipoprotein trafficking alterations, such as miR-128-1, miR-148a, miR-130b, and miR-301b. These miRNAs were able to increase circulating cholesterol by controlling the expression level of LDLR and ABCA1.

8These data suggest the participation of miRNAs in the control of cholesterol metabolism, underlining how they could contribute to the alteration of cholesterol levels when dysregulated.

Cholesterol Homeostasis in Normal and Cancer Cells

9Considering the importance of cholesterol metabolism, its cellular homeostasis is strictly regulated at every stage: import, synthesis, export, transport, and esterification. Sterol regulatory element-binding protein 2 (SREBF2) and LXRs act as key regulators of cholesterol homeostasis. In the ER, cholesterol itself regulates its homeostasis. Low cholesterol levels induce translocation of SREBP2 to the nucleus where it promotes activation of genes implicated in the biosynthesis (e.g., HMGCR) and uptake (e.g., LDLR) of cholesterol. High cholesterol levels inhibit the cholesterol synthesis and facilitate its export through the activation of LXRs by oxysterols, oxidized derivatives of cholesterol. Recent studies on LNCaP prostate cancer cells highlighted an important protective role of LXRs. In fact, the activation of these transcription factors regulating cholesterol homeostasis was able to induce cell cycle arrest and to promote apoptosis. The relationship among LXRs, cholesterol, and prostate cancer highlights that LXRs have good chance to be targeted one day in this tumor.

10During cholesterol biosynthesis, depending on the type of tissue, different intermediate sterols are formed, such as cholesteryl ester, oxysterols, bile acids, cholecalciferol/vitamin D, and various steroid hormones. All these sterols have important physiological functions in cells and in tissues. Some cholesterol metabolites may also contribute to the progression and metastatization of some types of cancer.

11Under healthy conditions, the amount of cholesterol is the result of a balance between synthesis, uptake from extracellular milieu, removal of the cholesterol surplus from peripheral tissues, and metabolic conversion (; Figure 3). The alterations of this balance, often caused by unbalanced diets and unhealthy lifestyles, are known to be associated with cardiovascular diseases and atherosclerosis, but mounting evidence also connects these behaviors to increased cancer risks.

12Over the past few decades, literature data have demonstrated that metabolic alterations represent a hallmark of cancer. Oncogenesis is an intricate process that involves, in addition to reprogramming energy metabolism, also reprogramming of genetic information, signaling mechanisms, and structural components, which are critical for the survival and growth of cancer cells. Reprogramming energy metabolism had already been described by Otto Warburg, which highlighted that cancer cells, even in the presence of abundant oxygen, preferably produce ATP (adenosine triphosphate) through the less efficient glycolytic pathway, rather than through oxidative phosphorylation (OXPHOS), thus producing more lactate than normal cells. This metabolic switch of cancer cells, called Warburg effect, is also known as aerobic glycolysis. More recently, attention has been paid to metabolic heterogeneity within the tumor. Particular emphasis has been given to the cells present in the tumor stroma, which would also have the role of metabolically supporting the cancer cells. In this context fits the theory of the reverse Warburg effect according to which the aerobic glycolysis in the cells of the tumor stroma would have the role of providing, in addition to ATP, metabolites for the generation of further ATP through OXPHOS in cancer cells. Moreover, the metabolic coupling between stromal and tumor cell, with the exchange of useful metabolites, would also allow the tumor cell to increase its proliferation and reduce cell death.

13Alteration of energy metabolism is due to enhanced metabolic needs of cancer cells to support the proliferation, migration, and metastatic cancer activities. However, there are conflicting epidemiological evidence on the cholesterol function in cancer development, while important preclinical data suggested that a dysregulation of cholesterol homeostasis could lead to cancer progression. In particular, new data suggested that cholesterol amount in cells may have a greater role in cancer development than serum cholesterol. Some oncogenic pathways such as PI3K/AKT/mTOR, RTK/RAS, YAP/TAZ, and p53 are also able to regulate cholesterol production in cancer cells (Figure 4).

Cholesterol as Component of Lipid Rafts

14Besides the classical role of cholesterol in determining the correct structure, fluidity, and functioning of eukaryotic cell membranes, cholesterol represents the prevalent lipid component of specific plasma membrane microdomains, known as lipid rafts, also contributing to their organization. Indeed, cholesterol accumulates in specialized region of the membrane and, by interacting with sphingolipids, forms lipid rafts. These membrane regions are heterogeneous and highly dynamic structures, ranging from 10 to 200 nm in size, that selectively recruit and concentrate different membrane proteins (i.e., receptors, adhesion molecules, etc.) and signaling molecules, forming a sort of platform for signal transduction. Nitric oxide synthase, GPI-anchored proteins, Src-family tyrosine kinases, G-protein-α subunit, protein kinase C, and protein kinase A are typically localized within lipid rafts.

15Membrane and signaling proteins reside transiently within lipid rafts. Thus, depending on whether the signal transduction needs to be enhanced or damped, they can be recruited or excluded from lipid rafts in a reversible manner. The mechanisms at the base of reversible raft–protein associations are not yet completely understood. Characteristic lipid post-translational modifications have been described by researchers to be responsible for the recruitment of proteins within lipid rafts. One of the major raft-targeting signals is represented by S-palmitoylation of transmembrane proteins, consisting in palmitate moieties added to cysteine residues through thioester linkage. For instance, death receptors such as Fas/CD95 and TRAIL receptor 1 are palmitoylated on specific cysteine residues, and this event is essential either for their recruitment within lipid rafts or for an efficient transmission of death signals. In human breast cancer cells, palmitoylation of the surface adhesion receptor CD44 relies on two cysteine residues. This event enhances CD44 affinity for cholesterol-rich lipid rafts, inducing CD44 recruitment into lipid microdomains, limiting breast cancer cell migration. Moreover, proteins can be anchored to plasma membranes through a glycosylphosphatidylinositol (GPI) anchor or they can present a lysine-rich region within their amino acid sequence, which represents an additional signal beside palmitoylation targeting proteins within lipid rafts.

16Therefore, membrane lipid rafts represent a sort of lipid-based structures that regulate the assembly and functioning of numerous cell signaling, including those related to cancer, such as tumor cell growth, adhesion, migration, invasion, and apoptosis.

17Lipid rafts were also found in mitochondria, ER, in the nuclear membrane, and phagosomes, respectively, where they form a sort of “raft-like microdomain”. These regions, rich in gangliosides, present a content of cholesterol lower as compared with plasma membrane. They are involved in triggering specific events during apoptosis execution, i.e., mitochondria hyperpolarization and depolarization, with consequent release of apoptogenic factors, and regulation of fusion–fission processes.

18Taking into account all these considerations, the interest in targeting membrane raft cholesterol in cancer cells is increasing. Specific studies might be helpful to better understand the potential use of lipid rafts as innovative target in anti-cancer therapy.

Raft-Associated Cholesterol Involvement in Migration, Invasion, and Metastatic Processes of Cancer Cells

19Mounting evidence of the literature supports a role for lipid rafts in several signaling transduction pathway related to malignancy. Therefore, the interest in studying lipid rafts and the modulation of lipid raft organization is growing. Approaches aimed at disorganizing membrane raft domains were reported by researchers to affect cancer cell proliferation, adhesion, migration, invasiveness, metastatic spread, and apoptosis.

20A critical feature of malignancy is represented by the acquisition of a more aggressive phenotype by cancer cells. Because of their malignancy, cancer cells became able to adhere to the extracellular matrix and therefore to migrate and to invade other tissues, leading to metastasis. The plasma membrane certainly represents the first structure of the tumor cell to be involved in the processes of invasion and metastasis. Invadopodia are highly specialized plasma membrane structures of tumor cells, corresponding to podosomes of untransformed cells, able to favor the adhesion and penetration of the tumor cell into the underlying extracellular matrix, stroma, and basement membrane. The formation of invadopodia, structures rich in cytoskeletal elements, adhesion molecules, and degradative enzymes, requires the presence of lipid rafts, which are decisive for the establishment of this invasive and dynamic structure. found that Cav-1, a typical component of caveolar membrane lipid raft structures, represents an essential regulator of invadopodia-mediated human breast cancer cell invasion. Disruption of lipid rafts by depletion of membrane cholesterol using methyl-β-cyclodextrin (MβCD) suppressed either invadopodia formation and tumor invasion, thus providing evidence that lipid raft formation was mandatory for invadopodia functioning, at least in human breast cancer. In bladder cancer cells, Cav-1 overexpression induced epithelial-to-mesenchymal transition that was mediated by PI3K/AKT activation.

21Very interestingly, a reduced expression of Cav-1 was found frequently in human cancer-associated fibroblasts, where it was accompanied by a reduced mitochondrial function and an increased expression of glycolytic enzymes. Some studies have shown that tumor cells, inducing oxidative stress, were responsible for the autophagic degradation of Cav-1 in stromal fibroblast, thus favoring tumor–stroma co-evolution underlying the theory of the reverse Warburg effect.

22The dysregulation of flotillin-2, a protein marker of non-caveolar plasma membrane microdomains, has been reported in a variety of tumors. In particular, a recent study related a high expression of flotillin-2 to the incidence of lymph node metastasis and TNM stage in intrahepatic cholangiocarcinoma cell lines, as also previously observed in a variety of human solid tumors. High expression of flotillins was also observed in drug-resistant strains of colorectal cancer cells. Data from Ye and coworkers clearly demonstrated that flotillin silencing using lentivirus-mediated RNAi approach, by inducing destruction of lipid rafts, inhibited the drug resistance of the colorectal cancer cell line HCT-15.

23Additional findings in prostate cancer cells suggested a potential positive role of membrane cholesterol in modulating the IL-6/STAT3 pathway and chemoattraction. The IL6–JAK–STAT3 pathway, known to be an important signaling pathway in prostate cancer, requires intact lipid rafts for sustaining pro-oncogenic signaling. Also in this case, disruption of lipid rafts by MβCD inhibited this pathway thus controlling prostate cancer growth. In addition, it has also been reported that hypoxia, a prognostic predictor of poor clinical outcome, was able to increase cholesterol level and recruitment of Notch3 into lipid rafts. Notch3 activity sustained cell proliferation of different hormone-dependent and independent prostate cancer cell lines, and positively correlated with tumor aggressiveness. In prostate cancer cells, it has also been reported that the interaction of the tetraspanin CD82 with cholesterol in lipid rafts inhibited tumor cell movement and invasion by acting on plasma membrane/cytoskeleton linker ezrin, thus disengaging the plasma membrane–cytoskeleton connection and consequently repressing cell movement.

24Several proteins responsible for development of a more aggressive and metastatic phenotype have been found associated with lipid rafts, including integrins and cell adhesion molecules, ion channels, potassium channels, and MUC1, strongly supporting a positive role for lipid rafts in tumor progression.

25Several findings reported the localization within lipid rafts of the highly expressed cell surface adhesion receptor CD44, whose lipid raft localization was related to invasion and metastatic processes of cancer cells. In this context, it was reported that MβCD-mediated depletion of cholesterol induced CD44 shedding. Like MβCD, simvastatin, an agent that is able to target cholesterol with consequent disorganization of membrane rafts, also demonstrated to be effective in increasing shedding of CD44 and concomitantly in inhibiting tumor cell migration. In the same vein, it has also been shown that other statins induced disruption of lipid rafts, leading to impairment of tumor cell adhesion and migration.

26Like other receptors, CD44 has been found into lipid rafts or associated with the actin cytoskeleton through the ezrin protein in non-raft compartments. Once CD44 binds ezrin in non-raft compartments, it promotes cancer cell adhesion and migration in hepatocellular carcinoma cells. Similar results were also reported for breast cancer cells. Thus, CD44–ezrin interaction in non-raft compartments leads to cell migration. Taken together, these data point out the importance of lipid rafts in CD44-mediated migration and invasion processes, but the molecular mechanism involved remains to be fully elucidated. Taking into account all these evidences, lipid rafts might therefore represent an important modulator of the invasive and metastatic ability of cancer cells. Accordingly, it has demonstrated that suppressing lipid raft formation using the bioactive natural compound daphnane-type diterpenes from Daphne genkwa (GD) strongly impaired human hepatocellular carcinoma cell invasion and migration.

Raft-Associated Cholesterol in Cancer Cell Survival and Apoptosis

27Many studies in the literature evidenced cholesterol-rich rafts as important players regarding cancer cell survival signaling and proliferative pathway. Indeed, it has been reported that survival signal pathways are compartmentalized into lipid rafts where membrane receptors can become in close contact with downstream signaling molecules, inducing the transmission of proliferative signals into the cells. This is the case of the activation of PI3K/AKT-mediated survival signals induced by insulin-like growth factor. In fact, it has been reported that activation of IGF receptors induced the recruitment of several signaling molecules involved in the PI3K/AKT pathway into lipid rafts, favoring activation by phosphorylation of AKT, with subsequent transmission of survival signals into the cells. Disruption of lipid rafts using MβCD or filipin III had demonstrated efficacy in inhibiting the activation of AKT and other survival signaling pathways in human lung adenocarcinoma and human T-cell leukemia, in favor of apoptosis activation.

28Data obtained in prostate cancer highlighted the importance of the epidermal growth factor (EGF) receptor recruitment into lipid rafts for an efficient transmission of survival signal within the cells. Indeed, it has been reported that disruption of membrane rafts using statins, known cholesterol-lowering agents, impaired EGF receptor pathway, favoring apoptosis.

29Particular attention has also been paid by researchers on the role of lipid rafts regarding the apoptotic signaling pathway, which could occur following one of the two classical pathways, the extrinsic membrane receptor-mediated or the intrinsic mitochondria-involving pathway. Interestingly, cholesterol has emerged as key modulator of both apoptotic pathways. Like for cancer survival signaling, lipid rafts have been described as scaffold plasma membrane regions, in which death receptors and downstream signaling molecules (FADD, pro-caspase-8/-10) aggregate and cluster in, favoring apoptosis induction and execution. Findings from the last two decades evidenced that the localization of death receptors (e.g., CD95/FAS and TRAIL) into these specialized regions is mandatory either for susceptibility to receptor-mediated death signal or for a correct and efficient initiation of the apoptotic signaling (Figure 5;,;;,; ). Indeed, recruitment of the death receptor Fas/CD95 into lipid rafts has been described in several studies. Similarly, TRAIL death receptor 1, but not TRAIL death receptor 2, localized constitutively within the lipid rafts in human cancer B-cell lines, and this event was depicted as mandatory for an efficient death receptor-mediated signaling transduction. Actin cytoskeleton plays a peculiar role in ensuring a correct lipid localization of membrane proteins and an efficient cell death signal transmission. The ERM protein ezrin, known linker between membrane proteins and the actin cytoskeleton, was described as a positive regulator of early steps of Fas receptor signaling in lymphoid T cells. Moreover, aggregation of death receptors within lipid rafts, by promoting apoptosis induction, was favored by several agents, i.e., oxaliplatin, epirubicin, β-elemene, bufalin, resveratrol, ursodeoxycholic acid, edelfosine, and perifosine. On the contrary, agents able to disaggregate lipid rafts through membrane cholesterol depletion induced resistance to apoptotic cell death. For instance, resistance to TRAIL may be promoted by MβCD, whereas enhancement of TRAIL-induced apoptosis could be observed following perifosine treatment, which favored the recruitment of DRs into lipid rafts. Edelfosine-mediated upregulation of TRAIL-R2, and its subsequent increased recruitment within lipid rafts, turned resistant gastric cancer cells back to a TRAIL-sensitive phenotype. Enhanced Fas/CD95 recruitment and clustering within lipid rafts, and consequent increased Fas/CD95-mediated apoptosis, was observed after edelfosine treatment in several hematological malignancies. As a consequence, depletion of membrane cholesterol by leading to disruption of lipid rafts strongly impaired Fas/CD95 death signaling.

Targeting Cholesterol Pathways as Cancer Therapy

30Cancer has often been coupled with modifications in lipid metabolism, in particular in cholesterol metabolism. Alterations in cholesterol homeostasis have been identified in a large number of cancers. Both circulating and membrane associated cholesterol would appear to play a key role in the regulation of all cancer signaling pathways.

31According with this, it has been suggested that several anticancer drugs may have anti-proliferative function, limiting the content or production of cholesterol. For instance, it has been shown that doxorubicin caused the death of cancer cells by promoting a reduction in HMGCR levels and causing a decrease in cholesterol content. Other data displayed that tamoxifen modulated cholesterol metabolism in breast cancer cells. Many natural compounds, including terpenoids, green tea, garlic extract, and curcumin, effective in cancer prevention and therapy, were identified to target cholesterol homeostasis in cancer cells. Thus, these natural compounds might be useful in regulating cholesterol homeostasis as adjuvants to complement current anticancer therapies.

32The cholesterol synthesis pathway consists of a number of enzymes, each of which can represent a possible target to disturb the mevalonate pathway in cancer cells. Many studies suggested that pharmacological modulation of intracellular cholesterol balance could be effective in controlling cancer progression (Figure 6).

Targeting Cholesterol Synthesis and Uptake

33Cellular cholesterol levels are the result of a balance among the processes of production, transport, and storage. The biochemical events and the main players that in cells are underlying synthesis and trafficking cholesterol, and which, therefore, can represent potential therapeutic targets, are briefly mentioned in the following section.

HMGCR

34The rate-limiting reduction of HMG-CoA to mevalonate is an important regulatory step in cholesterol synthesis. HMG-CoA is highly regulated at transcriptional, translational, and post-translational planes. The HMGCR is an ER-localized glycoprotein that converts HMG-CoA to mevalonate. HMGCR is genetically activated by nSREBP2 when sterol concentrations are low. Sterols, mainly oxysterols, and two members of the vitamin E family can induce its degradation. Moreover, ubiquitination and proteasome-mediated degradation are also known mechanisms regulating HMGCR. HMGCR changes from a phosphorylated to a dephosphorylated form. Phosphorylation inhibits HMGCR activity. AMP-activated protein kinase (AMPK) is the main actor for hepatic HMGCR phosphorylation, which in turn results in hampering of cholesterol production when low intracellular ATP levels are perceived. Conversely, HMGCR-mediated cholesterol biosynthesis is triggered when AMPK suppression occurs. The interaction between HMGCR and the insulin-induced gene protein (INSIG-1 or -2) at ER membrane is pivotal to HMGCR ubiquitination and degradation. Overexpression of HMGCR has been well documented in gastric cancer cells, when it promoted growth and migration, while HMGCR knockdown inhibited growth, migration, and tumorigenesis. An upregulation of HMGCR was also observed in glioblastoma and prostate cancer.

35Statins were first used in the treatment of dyslipidemic disorders as therapeutic target to limiting production of mevalonate. In fact, statins are competitive inhibitors of HMGCR, and act by inhibiting the mevalonate pathway and reducing the end-product amounts such as cholesterol, isoprenoids, ubiquinone, and isopentenyladenine. Recently, a role in anti-cancer treatments has been proposed for statins. Literature data showed how the use of statins, alone or in combination with chemotherapeutic agents, could have anti-tumor effects and reduce the onset of multidrug resistance. As they have been shown very effective against mesenchymal-like cancer cells, Warita et al. have hypothesized their possible use during the transition from epithelial to mesenchymal phenotype of metastatic cells. It was reported that statin supply is effective in reducing the occurrence of a wide range of cancers (e.g., liver, gastric, colorectal, pancreatic, and prostate) and cancer-related mortality ratios.

SREBP

36Lipid homeostasis is controlled by membrane-bound transcription factors. These include the family of sterol regulatory element-binding proteins (SREBPs), which consist of three isoforms (SREBP1a, SREBP1c, and SREBP2). Among them, SREBP2 modulates more than 30 genes specific to the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. SREBPs are inactive when high cholesterol amounts are sensed and bound to SREBP cleavage activating protein (SCAP) and insulin-induced genes (INSIGs). Under cholesterol depletion conditions, feedback responses determine the dissociation of INSIGs from the SREBP2/SCAP complex, which move from the ER toward the Golgi apparatus. Subsequently, SREBP2 is processed and addressed to the nucleus. Nuclear SREBP2 (nSREBP2) induces the transcription of target genes, such as HMGCR and SQLE, by the direct interaction with the sterol regulatory element (SRE) motifs in their promoters. The upregulation of SREBP-activated downstream genes has been observed in a plethora of cancers, including glioblastoma, prostate cancer, breast cancer, and melanoma, and was often found associated with poor prognosis/survival. The increase of cholesterol synthesis is mediated by the activation of PI3K–AKT–mTORC1 signaling. In fact, PI3K–AKT pathway induced expression of SREBP genes and increased the stability of nuclear SREBPs by preventing their proteasomal degradation. Similarly, the transcription of nSREBP2 can also be induced by the mammalian target of rapamycin complex 1 (mTORC1) via inhibition of lipin-1. Results from preclinical studies showed that the AKT/mTORC1/SREBP pathway takes part in cancer cell growth by inducing biosynthesis of cholesterol. Finally, direct inhibition of SREBP2 (e.g., using fatostatin), resulting in a decrease in cholesterol content, may represent an interesting target in the treatment of a wide range of cancers.

SQLE

37Squalene epoxidase catalyzes the conversion of squalene to (S)-2,3-epoxysqualene (SQLE) and shares with HMGCR the low rates of catalysis in the cholesterol biosynthesis. Like HMGCR, SQLE abundance and activity are regulated at gene and protein levels. The SQLE gene responds to sterols via SREBP2 and the protein can be degraded in the presence of cholesterol by ubiquitination. HMGCR and SQLE are both transcriptionally controlled by nSREBP2, but they can lead to cholesterol biosynthesis independently of each other. In the presence of an excess of cholesterol, squalene epoxidase is degraded by the E3 ubiquitin ligase MARCH6.

38Robust scientific evidence demonstrated that SQLE can be considered an important oncogene and, consequently, may represent a possible target in cancer therapy. In particular, in vitro and in vivo studies have shown that SQLE could promote tumor cell proliferation and migration, and that treatment with its inhibitors (i.e., terbinafine or NB-598) could induce cancer cell demise. Moreover, a further study on nasopharyngeal carcinoma (NPC) linked the oncogenic effect of SQLE to the cholesteryl ester accumulation, which promoted NPC cell proliferation by activating the PI3K/AKT pathway. In the same vein, in hepatocellular carcinoma (HCC), the overexpression of SQLE was demonstrated to promote cell proliferation and migration by ERK signaling, while downregulation of SQLE was able to inhibit the tumorigenicity of HCC cells. In addition, SQLE overexpression seem to represent a negative prognostic factor both in breast and prostate cancers.

NPC1L1

39Niemann–Pick type C1-like 1 is the principal responsible for cholesterol absorption from dietary sources. It is a membrane protein expressed on the apical surface of enterocytes and on the membrane of bile canaliculi of human hepatocytes. Under normal growth conditions, NPC1L1 is present primarily in the endocytic recycling compartment and translocate rapidly to the plasma membrane upon cholesterol depletion. Supplying of cholesterol triggers the inward transport of NPC1L1 together with cholesterol from the plasma membrane to the endocytic recycling compartment. NPC1L1 can be sent back to the plasma membrane for recycling. This process requires, in addition to other proteins, the small GTPase CDC42 and actin filaments. The human NPC1L1 gene is activated by SREBP2. Moreover, NPC1L1 protein amount can be modulated by degradation.

40Recent literature data obtained both in vivo and in vitro indicated that NPC1L1 could represent a highly effective therapeutic target for treating pancreatic ductal adenocarcinoma (PDAC) because aberrant cholesterol uptake has been suggested to play a role in the proliferation and survival of pancreatic cancer cells. Accordingly, the use of ezetimibe, an inhibitor of NPC1L1 clinically used for the hypercholesterolemia treatment, significantly reduced the survival capacity of PDAC cells and tumor-associated blood vessel development.

LDLR

41Low-density lipoprotein receptor is a cell surface glycoprotein, which causes cellular absorption of cholesterol carried by the bloodstream. LDLR is the transcriptional target of SREBP2 and thyroid hormones. LDLR binds circulating LDLs to clathrin-coated vesicles, which then accede the endocytic pathway. The endosome acidity induces conformational modifications that allow detaching LDLR from LDLs. LDLR is then redirected to the cell surface for further endocytic cycles or it is addressed to lysosomes for degradation. After endocytosis, lysosomal lipase hydrolyzes LDL-carried CE and produces cholesterol, which is finally exported by the coordinate actions of NPC2, NPC1, and LAMP2. Inhibition of the LDLR at any level (e.g., biosynthesis, membrane localization, internalization, recycling, and degradation) can affect its availability or functionality and, consequently, LDL removal. LXRs bind to promoter of a LDLR inhibitor (IDOL) and upregulate its expression. Accordingly, using synthetic LXR agonists decreased LDLR abundance and limited LDL uptake in cultured cells and livers of non-human primates. The increased PCSK9 binding with LDLR prevents LDLR recycling and promotes its degradation in lysosomes. Several studies performed by using LXR agonists showed that cholesterol levels of glioblastoma cells decreased after stimulation of LXRs. The cholesterol decrement is due to enhanced cholesterol export and reduction of cholesterol import. LXR agonists also suppressed metastases of melanoma and prolonged animal survival in several in vivo models. In human cancers, the upregulation of PI3K–AKT–mTORC1 signaling promoted cellular cholesterol accumulation trough stimulation of LDLR-mediated cholesterol import. In glioblastoma, the overexpression of LDLR was caused by AKT, and pharmacological inhibition of LDLR actually favored cancer cell death. As mentioned previously, the increase of oxysterol, a by-product of cholesterol biosynthesis, was able to activate LXRs, which have been proposed as therapeutic targets in multiple cancer types.

SOAT

42Sterol-o-acyltransferase (SOAT) is a protein of the rough surface ER responsible for cholesteryl ester (CE) production from cholesterol and long-chain fatty acids. SOAT plays an important function by regulating cellular cholesterol storage and free cholesterol content. Because SOAT has a key role in regulating cellular cholesterol metabolism, it may represent a potential target for treatment of different sickness, including cancer. For instance, it is well known that cholesterol esterification and lipid droplet formation are typical features of glioblastoma (GBM). In fact, accumulation of lipid droplets in the tumor in patients with glioma correlated with GBM progression and poor survival. Genetic inhibition of SOAT1 to block cholesterol esterification was observed to suppress GBM growth and prolong the survival in xenograft models. In addition, literature data also demonstrated that treating adrenocortical carcinoma (ACC) with mitotane reduced cancer cell survival by inhibiting SOAT1 activity. Very recently, Jiang and colleagues also highlighted that the high expression of SOAT1 was associated with a poor prognosis in hepatocellular carcinoma, whereas its inhibition suppressed cell proliferation and migration.

Pyrophosphates

43Different enzymes involved in the biosynthesis of cholesterol could be targeted by anticancer drugs. Farnesyl transferase (FTase) and geranylgeranyl transferases (GGTase) are enzymes that catalyzed the production of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), both involved in cellular protein prenylation. The prenylation method consists in covalent bonds of hydrophobic molecules (both the C-15 isoprene farnesyl and the C-20 isoprene geranylgeranyl groups) to the C-terminal portion of different proteins, including the small GTP-binding proteins (sGTPases). sGTPases represent the greater and better described class of prenylated proteins. Each member of the Ras, Rho, and Rab GTPase families, many of which are involved in tumorigenesis, requires the structural alteration given by prenylation to bind to cell surface. Such posttranslational modifications and activation of GTP-binding proteins play a key function in most significant cellular processes. Inhibition of the mevalonate pathway reducing the isoprenylation of sGTPases could bring tumor cell death. Because the administration of GGPP and FPP prevented cancer cell death, it has been hypothesized that GGPP and FPP were necessary for the survival of cancer cells. It has been shown that bisphosphonates (BP) were able to block FPP synthase during the production of mevalonate, thus decreasing the formation of FPP and GGPP. Although BPs blocking osteoclast-mediated bone resorption are currently considered the most significant pharmaceutical treatment for metabolic bone disease, recently nitrogen-containing BPs have aroused interest in their antitumor properties.

Steroid Hormones

44Cholesterol is the precursor molecule of five different groups of steroid hormones synthesized by specific organs, the adrenal cortex and the gonads. Steroid hormones are widely known to control growth and differentiation. Moreover, steroid hormones are closely linked with the progression of ovarian, breast, and prostate cancers. According with this, inhibition of estrogen or androgen signaling represents the most used strategy in the treatment of these hormone-dependent tumors. With regard to prostate cancer, although almost all patients with metastatic disease initially respond to androgen-ablation therapies, unfortunately the majority of patients progress to a castrate-resistant stage. There is accumulating evidence suggesting that cholesterol, as a precursor of steroid hormones, effects on breast and prostate cancers. In this regard, it was observed that in vitro treatment of prostate and breast cancer cells with mevalonate was able to induce a high proliferation rate.

Targeting Cholesterol Transport

45To keep the cellular cholesterol levels constant, it is necessary that the excess cholesterol is carried out of the cell, and this can take place through active export and passive diffusion. Active export requires energy and involves several ABC transporter proteins using ATP. Passive diffusion is caused by a difference in cholesterol content between the cell membrane and cholesterol acceptors such as HDL.

LDLs/HDLs

46Cholesterol is a highly insoluble molecule that is transported in the bloodstream via lipoproteins LDLs and HDLs. Cells can acquire exogenous cholesterol from LDLs that carry abundant cholesterol esters. LDL initially binds to the LDLR receptor on the plasma membrane and is subsequently internalized by clathrin vesicles. In LDL, the lipase activity degrades esterified cholesterol producing free cholesterol, which is internalized by the plasma membrane and reaches the endosome/lysosome. ApoA-I is one of the best known HDL apolipoproteins, capable of binding cholesterol and phospholipids. HDLs bind and carry excess cholesterol from peripheral tissues to the liver where cholesterol is transformed into bile acids for excretion (reverse cholesterol transport). Lipoproteins are involved in the elaboration and transport of dietary cholesterol to tissues and aid in keeping a constant level of cholesterol by removing its excess to carry it to the liver. Therefore, lipoproteins could be involved in tumor progression by promoting the availability of cholesterol to tumor cells.

ABCA1

47ATP-binding cassette transporters are drug efflux pumps that can cause multidrug resistance and tumor treatment failure. Regarding ABCA1, it is responsible for the bidirectional transport of cholesterol across the cell surface, regulating its availability within the cell. In addition, it mediates the export of cholesterol and phospholipids in ApoA-I for HDL assembly. Some research works with Abca1 knockout mice have shown that both hepatic and intestinal ABCA1 concur to the production of total plasma HDL, although to varying degrees. ABCA1 localizes both at the plasma membrane, where it mediates the assembly of nascent HDLs, and at the endocytic compartments, where it is degraded or recycled from the plasmatic membrane. An excess of ABCA1 generates deformation sites in the plasma membrane, where apoA-I binds. This could be a result of the disturbing action of ABCA1 on lipid raft organization. In contrast, ABCA1 deficiency has been found to increase lipid rafts and cholesterol contents in the plasma membrane. ABCA1 is closely regulated both at gene and protein levels. LXRs are mainly responsible for activating the ABCA1 gene. Accordingly, data obtained in vitro by using LXR agonists revealed that the activation of LXR reduced intracellular cholesterol amount by increasing its exportation and decreasing its absorption therefore determining a growth inhibition of glioblastoma cells. Moreover, LXR agonists suppressed melanoma metastases and prolonged animal survival in several in vivo models.

48On the other hand, it was also reported the PI3K/AKT signaling, through the inhibition of ABCA1 mTORC1-dependent pathway, resulted in an increase of intracellular level of cholesterol. Rapamycin, the mTORC1 inhibitor, repressed the cholesterol export due to the action of ABCA1.

49Finally, the regulation of ABCA1 gene was also modulated by some miRNAs, including miR-33a/b and miR-148. These miRNAs suppressed ABCA1 gene expression and reduced plasma HDL levels in mice and non-human primates.

ACAT

50Acetyl-CoA acetyltransferase 1 and 2 (ACAT1 and ACAT2, respectively) play an important role in lipid metabolism. After esterification into CEs by ACAT1, surplus cholesterol can be stored as lipid droplets. ACAT1 overexpression and CE accumulation were found to play pro-tumor functions. In fact, it was observed that ACAT1 induced an excessive storage of cholesterol in lipid droplets in prostate, pancreatic cancers, and glioblastoma. According with this, ACAT1 inhibition was found to reduce migration of breast cancer cells and decrease prostate cancer progression. Moreover, ACAT1 inactivation determined abundant ER cholesterol content, which is acting on SREBP-1 reduced cholesterol synthesis and uptake. Recently, pharmacological or genetic ACAT1 inhibition has been associated with attenuated cancer cell proliferation.

51In light of all this, ACAT1 can be considered a possible therapeutic target for the treatment of some neoplasms linked to the abundant presence of cholesterol esters. The use of avasimibe, an effective inhibitor of ACAT1, remarkably decreased cholesteryl esters stocked in lipid droplets and enhanced free cholesterol amount into the cell in human prostate, pancreatic, lung, glioblastoma, and colon cancer cells leading to inhibition of proliferation, cell cycle arrest, and apoptosis.

Conclusion

52As the metabolic needs of cancer cells appear significantly different from non-cancer cells, the metabolic pathways could represent potential innovative targets for a more selective anticancer therapy.

53The analysis of literature data confirmed a fundamental role of cholesterol and its metabolism in many and different human pathologies, including atherosclerosis, Alzheimer’s disease, and other neurodegenerative disorders, and mounting evidence connected cholesterol homeostasis disorder and cancer. Moreover, dysregulation of the mevalonate pathway has been found to promote cell transformation, thus suggesting the role of oncogene for HMG-CoA reductase. All of this makes cholesterol a potential attractive pharmacological target also in oncology context. Accordingly, although quite controversial, preclinical and epidemiological data seem to show an antitumor activity of statins, at least against some types of cancer.

54At present, several drugs targeting cholesterol metabolism besides statins are clinically used to inhibit cholesterol production and increase LDL absorption, to hinder NPC1L1 absorption of dietary cholesterol and LDLR degradation, and to reduce plasma LDLs. For instance, the cholesterol uptake-blocking agent ezetimibe, by decreasing circulating cholesterol levels, has been found to reduce prostate tumor growth.

55Moreover, an increasing number of preclinical and clinical studies are underway to define as new potential therapeutic target for cancer therapy SREBP and its regulators LXRs, the transporters ABCs, and ACATs.

56Increasing evidence showed that also cholesterol-rich raft membrane domains could represent a promising target in cancer therapy. Indeed, acting as scaffolds for signaling pathways in the cell membrane, lipid rafts promote and facilitate the triggering of both survival and apoptosis by recruiting signaling molecules and death receptors. In this regard, understanding how the different rafts that promote cell survival or death are temporarily formed and disrupted may be an important goal to understand if and how lipid rafts could represent a specific target in cancer therapy.

57Finally, it is important to underline the key role played by the intestinal microbiota in the reduction and elimination of cholesterol, thus contributing significantly to its homeostasis. An alteration of the bacterial flora could constitute a further risk factor, especially for those tumors particularly dependent on cholesterol homeostasis. Thus, acting on microbiota might also represent a further possibility of therapeutic intervention in the treatment and/or prevention of certain types of cancer.

Author Contributions

58RV contributed to conceive the idea, drafted the article, and drew figures relative to cholesterol metabolism. EI contributed to design and to draft the article and drew figures relative to lipid rafts. PM conceived the idea, draft and revised the article, coordinated the activity, and concurred to the final version of the review. All authors contributed to the article and approved the submitted version.

Conflict of Interest

59The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 256

1.
Adler E.M. (2011 ). Lost without a raft. Sci. Sign. 4:c24. s
Not in our library10.1126/scisignal.4157ec24
2.
Akashi T. Koizumi K. Tsuneyama K. Saiki I. Takano Y. Fuse H. (2008 ). Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 99 539–542.
Not in our library10.1111/j.1349-7006.2007.00712.x
3.
Algeciras-Schimnich A. Shen L. Barnhart B.C. Murmann A.E. Burkhardt J.K. Peter M.E. (2002 ). Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22 207–220.
Not in our library10.1128/mcb.22.1.207-220.2002
4.
Altmann S.W. Davis H.R. Jr. Zhu L.J. Yao X. Hoos L.M. Tetzloff G. (2004 ). Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303 1201–1204.
Not in our library10.1126/science.1093131
5.
Annunziata I. Sano R. d’Azzo A. (2018 ). Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. Cell. Death Dis. 9:328.
Not in our library10.1038/s41419-017-0025-4
6.
Antalis C.J. Arnold T. Rasool T. Lee B. Buhman K.K. Siddiqui R.A. (2010 ). High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res. Treat 122 661–670.
Not in our library10.1007/s10549-009-0594-8
7.
Antharam V.C. McEwen D.C. Garrett T.J. Dossey A.T. Li E.C. Kozlov A.N. (2016 ). An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in clostridium difficile infection. PLoS One 11:e0148824.
Not in our library10.1371/journal.pone.0148824
8.
Asano K. Kubo M. Yonemoto K. Doi Y. Ninomiya T. Tanizaki Y. (2008 ). Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the hisayama study. Int. J. Cancer 122 909–914.
Not in our library10.1002/ijc.23191
9.
Asterholm I.W. Mundy D.I. Weng J. Anderson R.G. Scherer P.E. (2012 ). Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell. Metab. 15 171–185.
Not in our library10.1016/j.cmet.2012.01.004
10.
Babina I.S. McSherry E.A. Donatello S. Hill A.D. Hopkins A.M. (2014 ). A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Res. 16:R19.
Not in our library10.1186/bcr3614
11.
The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells · 2017
No notice
12.
CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL · 2016
No notice
13.
Benakanakere I. Johnson T. Sleightholm R. Villeda V. Arya M. Bobba R. (2014 ). Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells. Exp. Hematol. Oncol. 3:24.
Not in our library10.1186/2162-3619-3-24
14.
Benny S. Mishra R. Manojkumar M.K. Aneesh T.P. (2020 ). From warburg effect to reverse warburg effect; the new horizons of anti-cancer therapy. Med. Hypotheses 144:110216.
Not in our library10.1016/j.mehy.2020.110216
15.
Berndt N. Hamilton A.D. Sebti S.M. (2011 ). Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11 775–791.
Not in our library10.1038/nrc3151
16.
Borel F. Han R. Visser A. Petry H. van Deventer S.J. Jansen P.L. (2012 ). Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55 821–832.
Not in our library10.1002/hep.24682
17.
Boslem E. Weir J.M. MacIntosh G. Sue N. Cantley J. Meikle P.J. (2013 ). Alteration of endoplasmic reticulum lipid rafts contributes to lipotoxicity in pancreatic beta-cells. J. Biol. Chem. 288 26569–26582.
Not in our library10.1074/jbc.m113.489310
18.
The shape of human squalene epoxidase expands the arsenal against cancer · 2019
Not checked
19.
Brown D.A. London E. (2000 ). Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275 17221–17224.
Not in our library10.1074/jbc.r000005200
20.
Brown M.S. Goldstein J.L. (1986 ). A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746) 34–47.
Not in our library10.1126/science.3513311
21.
Brown M.S. Radhakrishnan A. Goldstein J.L. (2018 ). Retrospective on cholesterol homeostasis: the central role of scap. Annu. Rev. Biochem. 87 783–807.
Not in our library10.1146/annurev-biochem-062917-011852
22.
Brunham L.R. Kruit J.K. Iqbal J. Fievet C. Timmins J.M. Pape T.D. (2006 ). Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116 1052–1062.
Not in our library10.1172/jci27352
23.
Cascianelli G. Villani M. Tosti M. Marini F. Bartoccini E. Magni M.V. (2008 ). Lipid microdomains in cell nucleus. Mol. Biol. Cell. 19 5289–5295.
Not in our library10.1091/mbc.e08-05-0517
24.
Chakrabandhu K. Herincs Z. Huault S. Dost B. Peng L. Conchonaud F. (2007 ). Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 26 209–220.
Not in our library10.1038/sj.emboj.7601456
25.
Chang T.Y. Li B.L. Chang C.C. Urano Y. (2009 ). Acyl-coenzyme a:cholesterol acyltransferases. Am. J. Physiol. Endocrinol. Metab. 297 E1–E9.
Not in our library10.1152/ajpendo.90926.2008
26.
Chen L. Ma M.Y. Sun M. Jiang L.Y. Zhao X.T. Fang X.X. (2019 ). Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing. J. Lipid Res. 60 1765–1775.
Not in our library10.1194/jlr.ra119000201
27.
Chinni S.R. Yamamoto H. Dong Z. Sabbota A. Bonfil R.D. Cher M.L. (2008 ). CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 6 446–457.
Not in our library10.1158/1541-7786.mcr-07-0117
28.
Chua N.K. Coates H.W. Brown A.J. (2018 ). Cholesterol, cancer, and rebooting a treatment for athlete’s foot. Sci. Transl. Med. 10:eaat3741.
Not in our library10.1126/scitranslmed.aat3741
29.
Chushi L. Wei W. Kangkang X. Yongzeng F. Ning X. Xiaolei C. (2016 ). HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene 587 42–47.
Not in our library10.1016/j.gene.2016.04.029
30.
Ciarlo L. Manganelli V. Garofalo T. Matarrese P. Tinari A. Misasi R. (2010 ). Association of fission proteins with mitochondrial raft-like domains. Cell. Death Differ. 17 1047–1058.
Not in our library10.1038/cdd.2009.208
31.
Ciarlo L. Vona R. Manganelli V. Gambardella L. Raggi C. Marconi M. (2018 ). Recruitment of mitofusin 2 into “lipid rafts” drives mitochondria fusion induced by Mdivi-1. Oncotarget 9 18869–18884.
Not in our library10.18632/oncotarget.24792
32.
Cirmena G. Franceschelli P. Isnaldi E. Ferrando L. De Mariano M. Ballestrero A. (2018 ). Squalene epoxidase as a promising metabolic target in cancer treatment. Cancer Lett. 425 13–20.
Not in our library10.1016/j.canlet.2018.03.034
33.
Clendening J.W. Pandyra A. Boutros P.C. El Ghamrasni S. Khosravi F. Trentin G.A. (2010 ). Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U S A. 107 15051–15056.
Not in our library10.1073/pnas.0910258107
34.
Costet P. Luo Y. Wang N. Tall A.R. (2000 ). Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275 28240–28245.
Not in our library10.1074/jbc.m003337200
35.
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics · 2013
No notice
36.
Dambal S. Alfaqih M. Sanders S. Maravilla E. Ramirez-Torres A. Galvan G.C. (2020 ). 27-Hydroxycholesterol impairs plasma membrane lipid raft signaling as evidenced by inhibition of IL6-JAK-STAT3 signaling in prostate cancer cells. Mol. Cancer Res. 18 671–684.
Not in our library10.1158/1541-7786.mcr-19-0974
37.
Daniil G. Zannis V.I. Chroni A. (2013 ). Effect of apoA-I mutations in the capacity of reconstituted HDL to promote ABCG1-mediated cholesterol efflux. PLoS One 8:e67993.
Not in our library10.1371/journal.pone.0067993
38.
Danza G. Di Serio C. Ambrosio M.R. Sturli N. Lonetto G. Rosati F. (2013 ). Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int. J. Cancer 133 2577–2586.
Not in our library10.1002/ijc.28293
39.
Deeley R.G. Westlake C. Cole S.P. (2006 ). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 86 849–899.
Not in our library10.1152/physrev.00035.2005
40.
Delmas D. Rebe C. Micheau O. Athias A. Gambert P. Grazide S. (2004 ). Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 8979–8986.
Not in our library10.1038/sj.onc.1208086
41.
Denis M. Landry Y.D. Zha X. (2008 ). ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J. Biol. Chem. 283 16178–16186.
Not in our library10.1074/jbc.m709597200
42.
Ding X. Zhang W. Li S. Yang H. (2019 ). The role of cholesterol metabolism in cancer. Am. J. Cancer Res. 9 219–227.
Not in our library
43.
Donatello S. Babina I.S. Hazelwood L.D. Hill A.D. Nabi I.R. Hopkins A.M. (2012 ). Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. Am. J. Pathol. 181 2172–2187.
Not in our library10.1016/j.ajpath.2012.08.025
44.
Dong F. Mo Z. Eid W. Courtney K.C. Zha X. (2014 ). Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1. PLoS One 9:e113789.
Not in our library10.1371/journal.pone.0113789
45.
DuBroff R. de Lorgeril M. (2015 ). Cholesterol confusion and statin controversy. World J. Cardiol. 7 404–409.
Not in our library10.4330/wjc.v7.i7.404
46.
Duvel K. Yecies J.L. Menon S. Raman P. Lipovsky A.I. Souza A.L. (2010 ). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 39 171–183.
Not in our library10.1016/j.molcel.2010.06.022
47.
Ettinger S.L. Sobel R. Whitmore T.G. Akbari M. Bradley D.R. Gleave M.E. (2004 ). Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64(6) 2212–2221.
Not in our library10.1158/0008-5472.can-2148-2
48.
Fan W. Chang J. Fu P. (2015 ). Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med. Chem. 7 1511–1519.
Not in our library10.4155/fmc.15.93
49.
Farwell W.R. Scranton R.E. Lawler E.V. Lew R.A. Brophy M.T. Fiore L.D. (2008 ). The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 100 134–139.
Not in our library10.1093/jnci/djm286
50.
Fedoseienko A. Wijers M. Wolters J.C. Dekker D. Smit M. Huijkman N. (2018 ). The COMMD family regulates plasma LDL levels and attenuates atherosclerosis through stabilizing the CCC complex in endosomal LDLR trafficking. Circ. Res. 122 1648–1660.
Not in our library10.1161/circresaha.117.312004
51.
Feig C. Tchikov V. Schutze S. Peter M.E. (2007 ). Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26 221–231.
Not in our library10.1038/sj.emboj.7601460
52.
Feinberg M.W. Moore K.J. (2016 ). MicroRNA regulation of atherosclerosis. Circ. Res. 118 703–720.
Not in our library10.1161/circresaha.115.306300
53.
Fu W. Yao J. Huang Y. Li Q. Li W. Chen Z. (2014 ). LXR agonist regulates the carcinogenesis of PCa via the SOCS3 pathway. Cell. Physiol. Biochem. 33 195–204.
Not in our library10.1159/000356662
54.
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR · 2015
Not checked
55.
Gajate C. Del Canto-Janez E. Acuna A.U. Amat-Guerri F. Geijo E. Santos-Beneit A.M. (2004 ). Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med. 200 353–365.
Not in our library10.1084/jem.20040213
56.
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. · 2009
Not checked
57.
Gajate C. Mollinedo F. (2001 ). The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98 3860–3863.
Not in our library10.1182/blood.v98.13.3860
58.
Gajate C. Mollinedo F. (2005 ). Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 280 11641–11647.
Not in our library10.1074/jbc.m411781200
59.
Gajate C. Mollinedo F. (2007 ). Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109 711–719.
Not in our library10.1182/blood-2006-04-016824
60.
Gajate C. Mollinedo F. (2014 ). Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. Anticancer Agents Med. Chem. 14 509–527.
Not in our library10.2174/1871520614666140309222259
61.
Gajate C. Mollinedo F. (2015a ). Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications. J. Leukoc Biol. 98 739–759.
Not in our library10.1189/jlb.2mr0215-055r
62.
Gajate C. Mollinedo F. (2015b ). Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling. Apoptosis 20 584–606.
Not in our library10.1007/s10495-015-1104-6
63.
Galbiati F. Volonte D. Meani D. Milligan G. Lublin D.M. Lisanti M.P. (1999 ). The dually acylated NH2-terminal domain of gi1alpha is sufficient to target a green fluorescent protein reporter to caveolin-enriched plasma membrane domains. Palmitoylation of caveolin-1 is required for the recognition of dually acylated g-protein alpha subunits in vivo. J. Biol. Chem. 274(9) 5843–5850.
Not in our library10.1074/jbc.274.9.5843
64.
Gao S. Shi Z. Li X. Li W. Wang Y. Liu Z. (2018 ). Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol. Rep. 39 1919–1929.
Not in our library10.3892/or.2018.6265
65.
Gao X. Lowry P.R. Zhou X. Depry C. Wei Z. Wong G.W. (2011 ). PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc. Natl. Acad. Sci. U S A. 108 14509–14514.
Not in our library10.1073/pnas.1019386108
66.
Gao X. Zhang J. (2008 ). Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol. Biol. Cell. 19 4366–4373.
Not in our library10.1091/mbc.e08-05-0449
67.
Gao X. Zhang J. (2009 ). Akt signaling dynamics in plasma membrane microdomains visualized by FRET-based reporters. Commun. Integr. Biol. 2 32–34.
Not in our library10.4161/cib.2.1.7420
68.
Garofalo T. Giammarioli A.M. Misasi R. Tinari A. Manganelli V. Gambardella L. (2005 ). Lipid microdomains contribute to apoptosis-associated modifications of mitochondria in T cells. Cell. Death Differ. 12 1378–1389.
Not in our library10.1038/sj.cdd.4401672
69.
Garofalo T. Manganelli V. Grasso M. Mattei V. Ferri A. Misasi R. (2015 ). Role of mitochondrial raft-like microdomains in the regulation of cell apoptosis. Apoptosis 20 621–634.
Not in our library10.1007/s10495-015-1100-x
70.
Garofalo T. Matarrese P. Manganelli V. Marconi M. Tinari A. Gambardella L. (2016 ). Evidence for the involvement of lipid rafts localized at the ER-mitochondria associated membranes in autophagosome formation. Autophagy 12 917–935.
Not in our library10.1080/15548627.2016.1160971
71.
Garofalo T. Misasi R. Mattei V. Giammarioli A.M. Malorni W. Pontieri G.M. (2003 ). Association of the death-inducing signaling complex with microdomains after triggering through CD95/Fas. Evidence for caspase-8-ganglioside interaction in T cells. J. Biol. Chem. 278 8309–8315.
Not in our library10.1074/jbc.m207618200
72.
Garofalo T. Tinari A. Matarrese P. Giammarioli A.M. Manganelli V. Ciarlo L. (2007 ). Do mitochondria act as “cargo boats” in the journey of GD3 to the nucleus during apoptosis? FEBS Lett. 581 3899–3903.
Not in our library10.1016/j.febslet.2007.07.020
73.
Gbelcova H. Lenicek M. Zelenka J. Knejzlik Z. Dvorakova G. Zadinova M. (2008 ). Differences in antitumor effects of various statins on human pancreatic cancer. Int. J. Cancer 122 1214–1221.
Not in our library10.1002/ijc.23242
74.
Ge L. Wang J. Qi W. Miao H.H. Cao J. Qu Y.X. (2008 ). The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell. Metab. 7 508–519.
Not in our library10.1016/j.cmet.2008.04.001
75.
Gelissen I.C. Harris M. Rye K.A. Quinn C. Brown A.J. Kockx M. (2006 ). ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc. Biol. 26 534–540.
Not in our library10.1161/01.atv.0000200082.58536.e1
76.
Geng F. Cheng X. Wu X. Yoo J.Y. Cheng C. Guo J.Y. (2016 ). Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Clin. Cancer Res. 22 5337–5348.
Not in our library10.1158/1078-0432.ccr-15-2973
77.
Gholkar A.A. Cheung K. Williams K.J. Lo Y.C. Hamideh S.A. Nnebe C. (2016 ). Fatostatin inhibits cancer cell proliferation by affecting mitotic microtubule spindle assembly and cell division. J. Biol. Chem. 291 17001–17008.
Not in our library10.1074/jbc.c116.737346
78.
Ginestier C. Monville F. Wicinski J. Cabaud O. Cervera N. Josselin E. (2012 ). Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 30 1327–1337.
Not in our library10.1002/stem.1122
79.
Goldstein J.L. Brown M.S. (1990 ). Regulation of the mevalonate pathway. Nature 343 425–430.
Not in our library10.1038/343425a0
80.
Goldstein J.L. Brown M.S. (2009 ). The LDL receptor. Arterioscler Thromb Vasc. Biol. 29 431–438.
Not in our library10.1161/atvbaha.108.179564
81.
Gong Y. Lee J.N. Lee P.C. Goldstein J.L. Brown M.S. Ye J. (2006 ). Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell. Metab. 3 15–24.
Not in our library10.1016/j.cmet.2005.11.014
82.
Guillaumond F. Bidaut G. Ouaissi M. Servais S. Gouirand V. Olivares O. (2015 ). Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. U S A. 112 2473–2478.
Not in our library10.1073/pnas.1421601112
83.
Guo D. Prins R.M. Dang J. Kuga D. Iwanami A. Soto H. (2009 ). EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Sign. 2:ra82.
Not in our library10.1126/scisignal.2000446
84.
Guo D. Reinitz F. Youssef M. Hong C. Nathanson D. Akhavan D. (2011 ). An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1 442–456.
Not in our library10.1158/2159-8290.cd-11-0102
85.
Haddon L. Hugh J. (2015 ). MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad. Clin. Exp. Metastasis 32 393–403.
Not in our library10.1007/s10585-015-9711-8
86.
Hanahan D. Weinberg R.A. (2000 ). The hallmarks of cancer. Cell 100 57–70.
Not in our library10.1016/s0092-8674(00)81683-9
87.
Hanahan D. Weinberg R.A. (2011 ). Hallmarks of cancer: the next generation. Cell 144 646–674.
Not in our library10.1016/j.cell.2011.02.013
88.
Heir T. Falk R.S. Robsahm T.E. Sandvik L. Erikssen J. Tretli S. (2016 ). Cholesterol and prostate cancer risk: a long-term prospective cohort study. BMC Cancer 16:643.
Not in our library10.1186/s12885-016-2691-5
89.
Horton J.D. Goldstein J.L. Brown M.S. (2002 ). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109(9) 1125–1131.
Not in our library10.1172/jci15593
90.
Howe V. Sharpe L.J. Prabhu A.V. Brown A.J. (2017 ). New insights into cellular cholesterol acquisition: promoter analysis of human HMGCR and SQLE, two key control enzymes in cholesterol synthesis. Biochim. Biophys. Acta. Mol. Cell. Biol. Lipids 1862 647–657.
Not in our library10.1016/j.bbalip.2017.03.009
91.
Hryniewicz-Jankowska A. Augoff K. Sikorski A.F. (2019 ). The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp. Biol. Med. (Maywood) 244 1053–1061.
Not in our library10.1177/1535370219870771
92.
Hu J. La Vecchia C. de Groh M. Negri E. Morrison H. Mery L. (2012 ). Dietary cholesterol intake and cancer. Ann. Oncol. 23 491–500.
Not in our library10.1093/annonc/mdr155
93.
Tetraspanin CD82 interaction with cholesterol promotes extracellular vesicle–mediated release of ezrin to inhibit tumour cell movement · 2020
Not checked
94.
Huang H. Tindall D.J. (2002 ). The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryot Gene. Expr. 12 193–207.
Not in our library10.1615/critreveukaryotgeneexpr.v12.i3.30
95.
Iessi E. Marconi M. Manganelli V. Sorice M. Malorni W. Garofalo T. (2020 ). On the role of sphingolipids in cell survival and death. Int. Rev. Cell. Mol. Biol. 351 149–195.
Not in our library10.1016/bs.ircmb.2020.02.004
96.
Ikonen E. (2008 ). Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell. Biol. 9 125–138.
Not in our library10.1038/nrm2336
97.
Jiang Y. Sun A. Zhao Y. Ying W. Sun H. Yang X. (2019 ). Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567 257–261.
Not in our library10.1038/s41586-019-0987-8
98.
Khan A.A. Agarwal H. Reddy S.S. Arige V. Natarajan B. Gupta V. (2020 ). MicroRNA 27a is a key modulator of cholesterol biosynthesis. Mol. Cell. Biol. 40:e470-19.
Not in our library10.1128/mcb.00470-19
99.
Kim J. Adam R.M. Solomon K.R. Freeman M.R. (2004 ). Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 145 613–619.
Not in our library10.1210/en.2003-0772
100.
Komati R. Spadoni D. Zheng S. Sridhar J. Riley K.E. Wang G. (2017 ). Ligands of therapeutic utility for the liver X receptors. Molecules 22:88.
Not in our library10.3390/molecules22010088
101.
Koseki M. Hirano K. Masuda D. Ikegami C. Tanaka M. Ota A. (2007 ). Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J. Lipid Res. 48 299–306.
Not in our library10.1194/jlr.m600428-jlr200
102.
Kuzu O.F. Noory M.A. Robertson G.P. (2016 ). The role of cholesterol in cancer. Cancer Res. 76 2063–2070.
Not in our library10.1158/0008-5472.can-15-2613
103.
Kwon H.J. Abi-Mosleh L. Wang M.L. Deisenhofer J. Goldstein J.L. Brown M.S. (2009 ). Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137 1213–1224.
Not in our library10.1016/j.cell.2009.03.049
104.
Landry Y.D. Denis M. Nandi S. Bell S. Vaughan A.M. Zha X. (2006 ). ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem. 281 36091–36101.
Not in our library10.1074/jbc.m602247200
105.
Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer · 2016
No notice
106.
Li J. Pfeffer S.R. (2016 ). Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. Elife 5:e21635.
Not in our library10.7554/elife.21635
107.
Li L. Zhang Q. Wang X. Li Y. Xie H. Chen X. (2020 ). Squalene epoxidase-induced cholesteryl ester accumulation promotes nasopharyngeal carcinoma development by activating PI3K/AKT signaling. Cancer Sci. 111 2275–2283.
Not in our library10.1111/cas.14426
108.
Liang W. Hao Z. Han J.L. Zhu D.J. Jin Z.F. Xie W.L. (2014 ). CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. Urol. Oncol. 32 855–863.
Not in our library10.1016/j.urolonc.2014.01.005
109.
Lim S.C. Duong H.Q. Choi J.E. Lee T.B. Kang J.H. Oh S.H. (2011 ). Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis 32 723–731.
Not in our library10.1093/carcin/bgr038
110.
Lim S.C. Parajuli K.R. Han S.I. (2016 ). The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway. Tumour Biol. 37 6205–6216.
Not in our library10.1007/s13277-015-4485-9
111.
Lin C.Y. Huo C. Kuo L.K. Hiipakka R.A. Jones R.B. Lin H.P. (2013 ). Cholestane-3beta, 5alpha, 6beta-triol suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS One 8:e65734.
Not in our library10.1371/journal.pone.0065734
112.
Lin C.Y. Vedin L.L. Steffensen K.R. (2016 ). The emerging roles of liver X receptors and their ligands in cancer. Exp. Opin. Ther. Targets 20 61–71.
Not in our library10.1517/14728222.2015.1081169
113.
Liu F.T. Qu Q.G. Zhu Z.M. (2017 ). Up-regulation of Flot-2 protein is related to lymph node metastasis and poor prognosis in human solid tumors. Minerva Chir. 72 146–156.
Not in our library10.23736/s0026-4733.16.07261-8
114.
Llaverias G. Danilo C. Mercier I. Daumer K. Capozza F. Williams T.M. (2011 ). Role of cholesterol in the development and progression of breast cancer. Am. J. Pathol. 178 402–412.
Not in our library10.1016/j.ajpath.2010.11.005
115.
Loh K. Tam S. Murray-Segal L. Huynh K. Meikle P.J. Scott J.W. (2019 ). Inhibition of adenosine monophosphate-activated protein kinase-3-hydroxy-3-methylglutaryl coenzyme a reductase signaling leads to hypercholesterolemia and promotes hepatic steatosis and insulin resistance. Hepatol. Commun. 3 84–98.
Not in our library10.1002/hep4.1279
116.
Longo J. Mullen P.J. Yu R. van Leeuwen J.E. Masoomian M. Woon D.T.S. (2019 ). An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol. Metab. 25 119–130.
Not in our library10.1016/j.molmet.2019.04.003
117.
Lopez D. Abisambra Socarras J.F. Bedi M. Ness G.C. (2007 ). Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim. Biophys. Acta 1771 1216–1225.
Not in our library10.1016/j.bbalip.2007.05.001
118.
Lorenzi I. von Eckardstein A. Radosavljevic S. Rohrer L. (2008 ). Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generates an interaction partner for ABCG1 but not for scavenger receptor BI. Biochim. Biophys. Acta 1781 306–313.
Not in our library10.1016/j.bbalip.2008.04.006
119.
Lozupone F. Lugini L. Matarrese P. Luciani F. Federici C. Iessi E. (2004 ). Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 279 9199–9207.
Not in our library10.1074/jbc.m305561200
120.
Lu-Yao G.L. Albertsen P.C. Moore D.F. Shih W. Lin Y. DiPaola R.S. (2014 ). Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern. Med. 174 1460–1467.
Not in our library10.1001/jamainternmed.2014.3028
121.
Lu R. Arakawa R. Ito-Osumi C. Iwamoto N. Yokoyama S. (2008 ). ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc. Biol. 28 1820–1824.
Not in our library10.1161/atvbaha.108.169482
122.
Lukanova A. Kaaks R. (2005 ). Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol. Biomark. Prev. 14 98–107.
Not in our library
123.
Luo J. Yang H. Song B.L. (2020 ). Mechanisms and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell. Biol. 21 225–245.
Not in our library10.1038/s41580-019-0190-7
124.
Emerging roles of lipid metabolism in cancer metastasis · 2017
No notice
125.
Malhotra P. Soni V. Yamanashi Y. Takada T. Suzuki H. Gill R.K. (2019 ). Mechanisms of niemann-pick type C1 Like 1 protein degradation in intestinal epithelial cells. Am. J. Physiol. Cell. Physiol 316 C559–C566.
Not in our library10.1152/ajpcell.00465.2018
126.
Malorni W. Giammarioli A.M. Garofalo T. Sorice M. (2007 ). Dynamics of lipid raft components during lymphocyte apoptosis: the paradigmatic role of GD3. Apoptosis 12(5) 941–949.
Not in our library10.1007/s10495-007-0757-1
127.
Marconi M. Ascione B. Ciarlo L. Vona R. Garofalo T. Sorice M. (2013 ). Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. Cell. Death Dis. 4:e863.
Not in our library10.1038/cddis.2013.389
128.
Martin T.A. Harrison G. Mansel R.E. Jiang W.G. (2003 ). The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol. 46 165–186.
Not in our library10.1016/s1040-8428(02)00172-5
129.
Martinez-Outschoorn U.E. Lisanti M.P. Sotgia F. (2014 ). Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25 47–60.
Not in our library10.1016/j.semcancer.2014.01.005
130.
Martinez-Outschoorn U.E. Trimmer C. Lin Z. Whitaker-Menezes D. Chiavarina B. Zhou J. (2010 ). Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell. Cycle 9 3515–3533.
Not in our library10.4161/cc.9.17.12928
131.
Matarrese P. Garofalo T. Manganelli V. Gambardella L. Marconi M. Grasso M. (2014 ). Evidence for the involvement of GD3 ganglioside in autophagosome formation and maturation. Autophagy 10 750–765.
Not in our library10.4161/auto.27959
132.
Maxfield F.R. Tabas I. (2005 ). Role of cholesterol and lipid organization in disease. Nature 438 612–621.
Not in our library10.1038/nature04399
133.
Maxfield F.R. van Meer G. (2010 ). Cholesterol, the central lipid of mammalian cells. Curr. Opin. Cell. Biol. 22 422–429.
Not in our library10.1016/j.ceb.2010.05.004
134.
McDonnell D.P. Park S. Goulet M.T. Jasper J. Wardell S.E. Chang C.Y. (2014 ). Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 74 4976–4982.
Not in our library10.1158/0008-5472.can-14-1756
135.
Mok E.H.K. Lee T.K.W. (2020 ). The pivotal role of the dysregulation of cholesterol homeostasis in cancer: implications for therapeutic targets. Cancers (Basel) 12:1410.
Not in our library10.3390/cancers12061410
136.
Mokarram P. Alizadeh J. Razban V. Barazeh M. Solomon C. Kavousipour S. (2017 ). Interconnection of estrogen/testosterone metabolism and mevalonate pathway in breast and prostate cancers. Curr. Mol. Pharmacol. 10 86–114.
Not in our library10.2174/1874467209666160112125631
137.
Mollinedo F. de la Iglesia-Vicente J. Gajate C. Estella-Hermoso de Mendoza A. Villa-Pulgarin J.A. Campanero M.A. (2010a ). Lipid raft-targeted therapy in multiple myeloma. Oncogene 29 3748–3757.
Not in our library10.1038/onc.2010.131
138.
Mollinedo F. de la Iglesia-Vicente J. Gajate C. Estella-Hermoso de Mendoza A. Villa-Pulgarin J.A. de Frias M. (2010b ). In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res. 16 2046–2054.
Not in our library10.1158/1078-0432.ccr-09-2456
139.
Mollinedo F. Gajate C. (2006 ). Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updat. 9(1-2) 51–73.
Not in our library10.1016/j.drup.2006.04.002
140.
Mollinedo F. Gajate C. (2010 ). Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol. 6 811–821.
Not in our library10.2217/fon.10.34
141.
Mollinedo F. Gajate C. (2015 ). Lipid rafts as major platforms for signaling regulation in cancer. Adv. Biol. Regul. 57 130–146.
Not in our library10.1016/j.jbior.2014.10.003
142.
Mollinedo F. Gajate C. (2020 ). Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy. J. Lipid Res. 61 611–635.
Not in our library10.1194/jlr.tr119000439
143.
Mollinedo F. Gajate C. Martin-Santamaria S. Gago F. (2004 ). ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. 11 3163–3184.
Not in our library10.2174/0929867043363703
144.
Motoyama K. Kameyama K. Onodera R. Araki N. Hirayama F. Uekama K. (2009 ). Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci. 38(3) 249–261.
Not in our library10.1016/j.ejps.2009.07.010
145.
Murai T. (2012 ). The role of lipid rafts in cancer cell adhesion and migration. Int. J. Cell. Biol. 2012:763283.
Not in our library10.1155/2012/763283
146.
Murai T. (2015 ). Cholesterol lowering: role in cancer prevention and treatment. Biol. Chem. 396 1–11.
Not in our library10.1515/hsz-2014-0194
147.
Murai T. Hokonohara H. Takagi A. Kawai T. (2009 ). Atomic force microscopy imaging of supramolecular organization of hyaluronan and its receptor CD44. IEEE Trans. Nanobiosci. 8 294–299.
Not in our library10.1109/tnb.2009.2035251
148.
Murai T. Maruyama Y. Mio K. Nishiyama H. Suga M. Sato C. (2011 ). Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration. J. Biol. Chem. 286 1999–2007.
Not in our library10.1074/jbc.m110.184010
149.
Murai T. Miyauchi T. Yanagida T. Sako Y. (2006 ). Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem. J. 395 65–71.
Not in our library10.1042/bj20050582
150.
Murai T. Miyazaki Y. Nishinakamura H. Sugahara K.N. Miyauchi T. Sako Y. (2004 ). Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem. 279 4541–4550.
Not in our library10.1074/jbc.m307356200
151.
Nagai M. Sakakibara J. Nakamura Y. Gejyo F. Ono T. (2002 ). SREBP-2 and NF-Y are involved in the transcriptional regulation of squalene epoxidase. Biochem. Biophys. Res. Commun. 295 74–80.
Not in our library10.1016/s0006-291x(02)00623-x
152.
Najafi-Shoushtari S.H. Kristo F. Li Y. Shioda T. Cohen D.E. Gerszten R.E. (2010 ). MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328 1566–1569.
Not in our library10.1126/science.1189123
153.
Nakashima J. Tachibana M. Horiguchi Y. Oya M. Ohigashi T. Asakura H. (2000 ). Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6 2702–2706.
Not in our library
154.
Nicolle R. Blum Y. Marisa L. Loncle C. Gayet O. Moutardier V. (2017 ). Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts. Cell. Rep. 21 2458–2470.
Not in our library10.1016/j.celrep.2017.11.003
155.
Nicolson G.L. (2015 ). Cell membrane fluid-mosaic structure and cancer metastasis. Cancer Res. 75 1169–1176.
Not in our library10.1158/0008-5472.can-14-3216
156.
Nielsen S.F. Nordestgaard B.G. Bojesen S.E. (2013 ). Statin use and reduced cancer-related mortality. N. Engl. J. Med. 368 576–577.
Not in our library10.1056/nejmc1214827
157.
Nooh A. Zhang Y.L. Sato D. Rosenzweig D.H. Tabaries S. Siegel P. (2017 ). Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. J. Bone Oncol 6 8–15.
Not in our library10.1016/j.jbo.2017.01.001
158.
Oh H.Y. Lee E.J. Yoon S. Chung B.H. Cho K.S. Hong S.J. (2007 ). Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 67 1061–1069.
Not in our library10.1002/pros.20593
159.
Oram J.F. Heinecke J.W. (2005 ). ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85 1343–1372.
Not in our library10.1152/physrev.00005.2005
160.
Ouvrier A. Cadet R. Vernet P. Laillet B. Chardigny J.M. Lobaccaro J.M. (2009 ). LXR and ABCA1 control cholesterol homeostasis in the proximal mouse epididymis in a cell-specific manner. J. Lipid Res. 50 1766–1775.
Not in our library10.1194/jlr.m800657-jlr200
161.
Parlato S. Giammarioli A.M. Logozzi M. Lozupone F. Matarrese P. Luciani F. (2000 ). CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19 5123–5134.
Not in our library10.1093/emboj/19.19.5123
162.
Patel H.H. Insel P.A. (2009 ). Lipid rafts and caveolae and their role in compartmentation of redox signaling. Antioxid Redox Signal 11 1357–1372.
Not in our library10.1089/ars.2008.2365
163.
Pelton K. Freeman M.R. Solomon K.R. (2012 ). Cholesterol and prostate cancer. Curr. Opin. Pharmacol. 12 751–759.
Not in our library10.1016/j.coph.2012.07.006
164.
Pencheva N. Buss C.G. Posada J. Merghoub T. Tavazoie S.F. (2014 ). Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156 986–1001.
Not in our library10.1016/j.cell.2014.01.038
165.
Peterson T.R. Sengupta S.S. Harris T.E. Carmack A.E. Kang S.A. Balderas E. (2011 ). mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146 408–420.
Not in our library10.1016/j.cell.2011.06.034
166.
Petrova E. Rios-Esteves J. Ouerfelli O. Glickman J.F. Resh M.D. (2013 ). Inhibitors of hedgehog acyltransferase block Sonic hedgehog signaling. Nat. Chem. Biol. 9 247–249.
Not in our library10.1038/nchembio.1184
167.
Molecular Mechanisms of Cellular Cholesterol Efflux · 2014
No notice
168.
Pike L.J. (2003 ). Lipid rafts: bringing order to chaos. J. Lipid Res. 44 655–667.
Not in our library10.1194/jlr.r200021-jlr200
169.
Pike L.J. (2006 ). Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J. Lipid Res. 47 1597–1598.
Not in our library10.1194/jlr.e600002-jlr200
170.
Pitroda S.P. Khodarev N.N. Beckett M.A. Kufe D.W. Weichselbaum R.R. (2009 ). MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc. Natl. Acad Sci. U S A. 106 5837–5841.
Not in our library10.1073/pnas.0812029106
171.
Pommier A.J. Alves G. Viennois E. Bernard S. Communal Y. Sion B. (2010 ). Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 29 2712–2723.
Not in our library10.1038/onc.2010.30
172.
Porstmann T. Santos C.R. Griffiths B. Cully M. Wu M. Leevers S. (2008 ). SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell. Metab. 8 224–236.
Not in our library10.1016/j.cmet.2008.07.007
173.
Pramfalk C. Davis M.A. Eriksson M. Rudel L.L. Parini P. (2005 ). Control of ACAT2 liver expression by HNF1. J. Lipid Res. 46 1868–1876.
Not in our library10.1194/jlr.m400450-jlr200
174.
Qiu Z. Yuan W. Chen T. Zhou C. Liu C. Huang Y. (2016 ). HMGCR positively regulated the growth and migration of glioblastoma cells. Gene 576 22–27.
Not in our library10.1016/j.gene.2015.09.067
175.
Radisauskas R. Kuzmickiene I. Milinaviciene E. Everatt R. (2016 ). Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina (Kaunas) 52 89–98.
Not in our library10.1016/j.medici.2016.03.002
176.
Rayner K.J. Esau C.C. Hussain F.N. McDaniel A.L. Marshall S.M. van Gils J.M. (2011 ). Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478 404–407.
Not in our library10.1038/nature10486
177.
Razani B. Rubin C.S. Lisanti M.P. (1999 ). Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J. Biol. Chem. 274 26353–26360.
Not in our library10.1074/jbc.274.37.26353
178.
Reis-Sobreiro M. Gajate C. Mollinedo F. (2009 ). Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 28 3221–3234.
Not in our library10.1038/onc.2009.183
179.
Reis-Sobreiro M. Roue G. Moros A. Gajate C. de la Iglesia-Vicente J. Colomer D. (2013 ). Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J. 3:e118.
Not in our library10.1038/bcj.2013.15
180.
Resh M.D. (1999 ). Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1451 1–16.
Not in our library10.1016/s0167-4889(99)00075-0
181.
Resh M.D. (2004 ). Membrane targeting of lipid modified signal transduction proteins. Subcell. Biochem. 37 217–232.
Not in our library10.1007/978-1-4757-5806-1_6
182.
Rogers M.A. Liu J. Song B.L. Li B.L. Chang C.C. Chang T.Y. (2015 ). Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): enzymes with multiple sterols as substrates and as activators. J. Steroid Biochem. Mol. Biol. 151 102–107.
Not in our library10.1016/j.jsbmb.2014.09.008
183.
Rossin A. Derouet M. Abdel-Sater F. Hueber A.O. (2009 ). Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J. 419 185–192.
Not in our library10.1042/bj20081212
184.
Rotllan N. Fernandez-Hernando C. (2012 ). MicroRNA regulation of cholesterol metabolism. Cholesterol 2012:847849.
Not in our library10.1155/2012/847849
185.
Rudenko G. Henry L. Henderson K. Ichtchenko K. Brown M.S. Goldstein J.L. (2002 ). Structure of the LDL receptor extracellular domain at endosomal pH. Science 298 2353–2358.
Not in our library10.1126/science.1078124
186.
Saraon P. Trudel D. Kron K. Dmitromanolakis A. Trachtenberg J. Bapat B. (2014 ). Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate 74 372–380.
Not in our library10.1002/pros.22758
187.
Sato R. (2010 ). Sterol metabolism and SREBP activation. Arch. Biochem. Biophys. 501 177–181.
Not in our library10.1016/j.abb.2010.06.004
188.
Sbiera S. Leich E. Liebisch G. Sbiera I. Schirbel A. Wiemer L. (2015 ). Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156 3895–3908.
Not in our library10.1210/en.2015-1367
189.
Scheel-Toellner D. Wang K. Singh R. Majeed S. Raza K. Curnow S.J. (2002 ). The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem. Biophys. Res. Commun. 297 876–879.
Not in our library10.1016/s0006-291x(02)02311-2
190.
Scorrano L. (2008 ). Caspase-8 goes cardiolipin: a new platform to provide mitochondria with microdomains of apoptotic signals? J. Cell. Biol. 183 579–581.
Not in our library10.1083/jcb.200810125
191.
Segala G. de Medina P. Iuliano L. Zerbinati C. Paillasse M.R. Noguer E. (2013 ). 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. Biochem. Pharmacol. 86 175–189.
Not in our library10.1016/j.bcp.2013.02.031
192.
Shah K. Gagliano T. Garland L. O’Hanlon T. Bortolotti D. Gentili V. (2020 ). Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing. Oncogene 39 6172–6189.
Not in our library10.1038/s41388-020-01429-2
193.
Silvente-Poirot S. Poirot M. (2012 ). Cholesterol metabolism and cancer: the good, the bad and the ugly. Curr. Opin. Pharmacol. 12 673–676.
Not in our library10.1016/j.coph.2012.10.004
194.
Simigdala N. Gao Q. Pancholi S. Roberg-Larsen H. Zvelebil M. Ribas R. (2016 ). Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 18:58.
Not in our library10.1186/s13058-016-0713-5
195.
Simons K. Ehehalt R. (2002 ). Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110 597–603.
Not in our library10.1172/jci16390
196.
Simons K. Ikonen E. (2000 ). How cells handle cholesterol. Science 290 1721–1726.
Not in our library10.1126/science.290.5497.1721
197.
Simons K. Toomre D. (2000 ). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell. Biol. 1 31–39.
Not in our library10.1038/35036052
198.
Solomon K.R. Freeman M.R. (2008 ). Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol. Metab. 19 113–121.
Not in our library10.1016/j.tem.2007.12.004
199.
Solomon K.R. Pelton K. Boucher K. Joo J. Tully C. Zurakowski D. (2009 ). Ezetimibe is an inhibitor of tumor angiogenesis. Am. J. Pathol. 174 1017–1026.
Not in our library10.2353/ajpath.2009.080551
200.
Song B.L. Javitt N.B. DeBose-Boyd R.A. (2005 ). Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell. Metab. 1 179–189.
Not in our library10.1016/j.cmet.2005.01.001
201.
Song K.S. Sargiacomo M. Galbiati F. Parenti M. Lisanti M.P. (1997 ). Targeting of a G alpha subunit (Gi1 alpha) and c-Src tyrosine kinase to caveolae membranes: clarifying the role of N-myristoylation. Cell. Mol. Biol. 43 293–303.
Not in our library
202.
Sorice M. Manganelli V. Matarrese P. Tinari A. Misasi R. Malorni W. (2009 ). Cardiolipin-enriched raft-like microdomains are essential activating platforms for apoptotic signals on mitochondria. FEBS Lett. 583 2447–2450.
Not in our library10.1016/j.febslet.2009.07.018
203.
Sorrentino G. Ruggeri N. Specchia V. Cordenonsi M. Mano M. Dupont S. (2014 ). Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell. Biol. 16 357–366.
Not in our library10.1038/ncb2936
204.
DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target · 2017
No notice
205.
Staubach S. Hanisch F.G. (2011 ). Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Exp. Rev. Proteomics 8 263–277.
Not in our library10.1586/epr.11.2
206.
Staubach S. Razawi H. Hanisch F.G. (2009 ). Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics 9 2820–2835.
Not in our library10.1002/pmic.200800793
207.
Stopsack K.H. Gerke T.A. Sinnott J.A. Penney K.L. Tyekucheva S. Sesso H.D. (2016 ). Cholesterol metabolism and prostate cancer lethality. Cancer Res. 76 4785–4790.
Not in our library10.1158/0008-5472.can-16-0903
208.
Sugii S. Reid P.C. Ohgami N. Du H. Chang T.Y. (2003 ). Distinct endosomal compartments in early trafficking of low density lipoprotein-derived cholesterol. J. Biol. Chem. 278 27180–27189.
Not in our library10.1074/jbc.m300542200
209.
Sui Z. Zhou J. Cheng Z. Lu P. (2015 ). Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells. Tumour Biol. 36 6173–6179.
Not in our library10.1007/s13277-015-3301-x
210.
Szajnman S.H. Ravaschino E.L. Docampo R. Rodriguez J.B. (2005 ). Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett. 15 4685–4690.
Not in our library10.1016/j.bmcl.2005.07.060
211.
Thurnher M. Nussbaumer O. Gruenbacher G. (2012 ). Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 18 3524–3531.
Not in our library10.1158/1078-0432.ccr-12-0489
212.
Timmins J.M. Lee J.Y. Boudyguina E. Kluckman K.D. Brunham L.R. Mulya A. (2005 ). Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115 1333–1342.
Not in our library10.1172/jci23915
213.
Vaupel P. Kelleher D.K. Hockel M. (2001 ). Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28 29–35.
Not in our library10.1016/s0093-7754(01)90210-6
214.
Vedhachalam C. Duong P.T. Nickel M. Nguyen D. Dhanasekaran P. Saito H. (2007 ). Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem. 282 25123–25130.
Not in our library10.1074/jbc.m704590200
215.
Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα · 2000
Not checked
216.
Vickers K.C. Landstreet S.R. Levin M.G. Shoucri B.M. Toth C.L. Taylor R.C. (2014 ). MicroRNA-223 coordinates cholesterol homeostasis. Proc. Natl. Acad. Sci. U S A. 111 14518–14523.
Not in our library10.1073/pnas.1215767111
217.
Villa G.R. Hulce J.J. Zanca C. Bi J. Ikegami S. Cahill G.L. (2016 ). An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell. 30 683–693.
Not in our library10.1016/j.ccell.2016.09.008
218.
Wagschal A. Najafi-Shoushtari S.H. Wang L. Goedeke L. Sinha S. deLemos A.S. (2015 ). Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat. Med. 21 1290–1297.
Not in our library10.1038/nm.3980
219.
Wang Y. Rogers P.M. Su C. Varga G. Stayrook K.R. Burris T.P. (2008 ). Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J. Biol. Chem. 283 26332–26339.
Not in our library10.1074/jbc.m804808200
220.
Warburg O. (1925 ). The metabolism of carcinoma cells. J. Cancer Res. 9 148–163.
Not in our library
221.
Warburg O. (1956 ). On the origin of cancer cells. Science 123 309–314.
Not in our library10.1126/science.123.3191.309
222.
Warita K. Warita T. Beckwitt C.H. Schurdak M.E. Vazquez A. Wells A. (2014 ). Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci. Rep. 4:7593.
Not in our library10.1038/srep07593
223.
Watson P.A. Arora V.K. Sawyers C.L. (2015 ). Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15 701–711.
Not in our library10.1038/nrc4016
224.
Wilde L. Roche M. Domingo-Vidal M. Tanson K. Philp N. Curry J. (2017 ). Metabolic coupling and the reverse warburg effect in cancer: implications for novel biomarker and anticancer agent development. Semin. Oncol. 44 198–203.
Not in our library10.1053/j.seminoncol.2017.10.004
225.
Wu J. Guo L. Qiu X. Ren Y. Li F. Cui W. (2020 ). Genkwadaphnin inhibits growth and invasion in hepatocellular carcinoma by blocking DHCR24-mediated cholesterol biosynthesis and lipid rafts formation. Br. J. Cancer 123 1673–1685.
Not in our library10.1038/s41416-020-01085-z
226.
Xie C. Li N. Chen Z.J. Li B.L. Song B.L. (2011 ). The small GTPase Cdc42 interacts with niemann-pick C1-like 1 (NPC1L1) and controls its movement from endocytic recycling compartment to plasma membrane in a cholesterol-dependent manner. J. Biol. Chem. 286 35933–35942.
Not in our library10.1074/jbc.m111.270199
227.
Xu L. Guo T. Qu X. Hu X. Zhang Y. Che X. (2018 ). beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts. Cell. Biol. Int. 42 1377–1385.
Not in our library10.1002/cbin.11023
228.
Xu L. Qu X. Luo Y. Zhang Y. Liu J. Qu J. (2011 ). Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts. Mol. Med. Rep. 4 407–411.
Not in our library10.3892/mmr.2011.439
229.
Xu L. Qu X. Zhang Y. Hu X. Yang X. Hou K. (2009 ). Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 583 943–948.
Not in our library10.1016/j.febslet.2009.02.014
230.
Xu X.D. Shao S.X. Jiang H.P. Cao Y.W. Wang Y.H. Yang X.C. (2015 ). Warburg effect or reverse warburg effect? A review of cancer metabolism. Oncol. Res. Treat 38 117–122.
Not in our library10.1159/000375435
231.
Xu Z. Wang T. Song H. Jiang X. (2020 ). Flotillin-2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma. Oncol. Lett. 19 2243–2250.
Not in our library10.3892/ol.2020.11349
232.
Yamaguchi H. Takeo Y. Yoshida S. Kouchi Z. Nakamura Y. Fukami K. (2009 ). Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res. 69 8594–8602.
Not in our library10.1158/0008-5472.can-09-2305
233.
Yamauchi Y. Furukawa K. Hamamura K. Furukawa K. (2011 ). Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: induction of the lipogenic pathway by a melanoma antigen. Cancer Res. 71 4989–4997.
Not in our library10.1158/0008-5472.can-10-4108
234.
Yamauchi Y. Iwamoto N. Rogers M.A. Abe-Dohmae S. Fujimoto T. Chang C.C. (2015 ). Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J. Biol. Chem. 290 23464–23477.
Not in our library10.1074/jbc.m115.662668
235.
Yamauchi Y. Reid P.C. Sperry J.B. Furukawa K. Takeya M. Chang C.C. (2007 ). Plasma membrane rafts complete cholesterol synthesis by participating in retrograde movement of precursor sterols. J. Biol. Chem. 282 34994–35004.
Not in our library10.1074/jbc.m703653200
236.
Yamauchi Y. Rogers M.A. (2018 ). Sterol metabolism and transport in atherosclerosis and cancer. Front. Endocrinol. (Lausanne) 9:509.
Not in our library10.3389/fendo.2018.00509
237.
Yan S. Qu X. Xu L. Che X. Ma Y. Zhang L. (2014 ). Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs 25 683–689.
Not in our library10.1097/cad.0000000000000095
238.
Yang B. Guo M. Herman J.G. Clark D.P. (2003 ). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 16 1101–1107.
Not in our library10.1016/s0002-9440(10)63469-4
239.
Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis in vivo · 2016
No notice
240.
Yang J. Wang L. Jia R. (2020 ). Role of de novo cholesterol synthesis enzymes in cancer. J. Cancer 11 1761–1767.
Not in our library10.7150/jca.38598
241.
Yang Y.F. Jan Y.H. Liu Y.P. Yang C.J. Su C.Y. Chang Y.C. (2014 ). Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. Am. J. Respir. Crit. Care Med. 190 675–687.
Not in our library10.1164/rccm.201404-0714oc
242.
Yang Z. Qin W. Chen Y. Yuan B. Song X. Wang B. (2018 ). Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts. Cancer Lett. 429 66–77.
Not in our library10.1016/j.canlet.2018.04.038
243.
Ye D.M. Ye S.C. Yu S.Q. Shu F.F. Xu S.S. Chen Q.Q. (2019 ). Drug-resistance reversal in colorectal cancer cells by destruction of flotillins, the key lipid rafts proteins. Neoplasma 66 576–583.
Not in our library10.4149/neo_2018_180820n633
244.
Yoshioka H. Coates H.W. Chua N.K. Hashimoto Y. Brown A.J. Ohgane K. (2020 ). A key mammalian cholesterol synthesis enzyme, squalene monooxygenase, is allosterically stabilized by its substrate. Proc. Natl. Acad. Sci. U S A. 117 7150–7158.
Not in our library10.1073/pnas.1915923117
245.
Yu L. Bharadwaj S. Brown J.M. Ma Y. Du W. Davis M.A. (2006 ). Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 281 6616–6624.
Not in our library10.1074/jbc.m511123200
246.
Yue S. Li J. Lee S.Y. Lee H.J. Shao T. Song B. (2014 ). Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell. Metab. 19 393–406.
Not in our library10.1016/j.cmet.2014.01.019
247.
Yun U.J. Lee J.H. Shim J. Yoon K. Goh S.H. Yi E.H. (2019 ). Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab. Invest. 99 1157–1172.
Not in our library10.1038/s41374-019-0193-1
248.
Zang M. Waelde C.A. Xiang X. Rana A. Wen R. Luo Z. (2001 ). Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. insights into mechanisms of Raf-1 activation. J. Biol. Chem. 276 25157–25165.
Not in our library10.1074/jbc.m100152200
249.
Zelcer N. Hong C. Boyadjian R. Tontonoz P. (2009 ). LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325 100–104.
Not in our library10.1126/science.1168974
250.
Zhang D.W. Garuti R. Tang W.J. Cohen J.C. Hobbs H.H. (2008 ). Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U S A. 105 13045–13050.
Not in our library10.1073/pnas.0806312105
251.
Zhang X. Song Y. Feng M. Zhou X. Lu Y. Gao L. (2015 ). Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J. Lipid Res. 56 963–971.
Not in our library10.1194/jlr.m047654
252.
Zhu X. Lee J.Y. Timmins J.M. Brown J.M. Boudyguina E. Mulya A. (2008 ). Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 283 22930–22941.
Not in our library10.1074/jbc.m801408200
253.
Zhuang L. Kim J. Adam R.M. Solomon K.R. Freeman M.R. (2005 ). Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115 959–968.
Not in our library10.1172/jci19935
254.
Zhuang L. Lin J. Lu M.L. Solomon K.R. Freeman M.R. (2002 ). Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 62 2227–2231.
Not in our library
255.
Zidovetzki R. Levitan I. (2007 ). Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim. Biophy.s Acta 1768 1311–1324.
Not in our library10.1016/j.bbamem.2007.03.026
256.
Zimber A. Chedeville A. Abita J.P. Barbu V. Gespach C. (2000 ). Functional interactions between bile acids, all-trans retinoic acid, and 1,25-dihydroxy-vitamin D3 on monocytic differentiation and myeloblastin gene down-regulation in HL60 and THP-1 human leukemia cells. Cancer Res. 60 672–678.
Not in our library

Cited by papers we hold 2

CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by modulating cholesterol metabolism in bladder cancer · 2025
Not checked
Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma · 2022
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.